EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A ROS‐Responsive Dual‐Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T‐Cell Acute Lymphoblastic Leukemia

Ruinan Jia, Yang Liu, Jilong Xiao, Yuan Xia, Xin Zhao, Huixian Ma, Jingjing Ye, Zhiyue Zhang, Tao Sun, Chunyan Ji iD

Advanced Science · 2025-08 · 12 (31)

DOI: 10.1002/advs.202505087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 31.05.2025. Verfasst von Ruinan Jia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, P. R. China. Hauptthemen laut MEDLINE: Ferroptosis, Reactive Oxygen Species, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Amyloid Precursor Protein Secretases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Distinguished Taishan Scholars in Climbing Plan, Young Taishan Scholars, Key Technology R&D and S/T Benefiting the People Demonstration Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T‐cell acute lymphoblastic leukemia (T‐ALL) is a highly aggressive hematological malignancy for which targeted therapies remain underdeveloped. Oncogenic mutations in Notch1 occur in up to 75% of T‐ALL patients. Although γ‐secretase inhibitors (GSIs) can block Notch1 activation, their clinical application is limited by side effects and reduced sensitivity. Here, a self‐assembling, reactive oxygen species (ROS)‐responsive nanotherapeutic strategy—PHD/G‐NPs—co‐loaded with GSI and controlled released dihydroartemisinin (DHA), and modified with a CD38 antibody is reported. The CD38 antibody specifically targets T‐ALL cells, while GSI selectively inhibits Notch1, resulting in a dual‐targeting approach. GSI is released first, inhibiting Notch1 activation and inducing the death of a subset of T‐ALL cells. To eliminate semi‐quiescent T‐ALL cells that escape initial therapy by elevating ROS levels, a ROS‐sensitive DHA delivery system is employed to enhance ferroptosis and boost GSI efficacy. After elucidating the mechanism of action of PHD/G‐NPs in T‐ALL cells, PHD/G‐NPs are combined with αPD‐1, which triggers an anti‐tumor immune response in vivo. This dual‐targeting strategy using CD38‐modified PHD/G‐NPs enables controlled drug release, enhances ferroptosis, mitigates GSI‐induced gastrointestinal toxicity, and improves therapeutic efficacy. This nanomedical approach offers a novel strategy for targeted T‐ALL treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisReactive Oxygen SpeciesPrecursor T-Cell Lymphoblastic Leukemia-LymphomaAmyloid Precursor Protein SecretasesDrug CarriersHumansAnimalsMiceCell Line, TumorNanoparticlesArtemisininsReceptor, Notch1

Stichwörter der Autor:innen

T‐cell acute lymphoblastic leukemia (T‐ALL)dihydroartemisinin (DHA)ferroptosisγ‐secretase inhibitors (GSIs)

Substanzen

Reactive Oxygen SpeciesAmyloid Precursor Protein SecretasesartenimolDrug CarriersArtemisininsReceptor, Notch1

Autor:innen und Institutionen

  • Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, P. R. China.
  • NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology (Ministry of Education), Shandong Key Laboratory of Targeted Drug Delivery and Advanced Pharmaceutics, Depa…
  • Cryomedicine Laboratory, Qilu Hospital of Shandong University, Jinan, Shandong Province, 250012, China.
  • Shandong Key Laboratory of Hematological Diseases and Immune Microenvironment, Qilu Hospital, Shandong University, Jinan, 250012, P. R. China.

ORCID-Profile: Chunyan Ji

Förderung

  • Distinguished Taishan Scholars in Climbing Plan
  • Young Taishan Scholars
  • Key Technology R&D and S/T Benefiting the People Demonstration Project
  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province
  • China Postdoctoral Science Foundation
  • Fundamental Research Funds for the Central Universities
  • Independently Cultivate Innovative Teams of Jinan, Shandong Province

Zitieren

APA

Jia, R., Liu, Y., Xiao, J., Xia, Y., Zhao, X., Ma, H., Ye, J., Zhang, Z., Sun, T., & Ji, C. (2025). A ROS‐Responsive Dual‐Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T‐Cell Acute Lymphoblastic Leukemia. Advanced Science, 12(31). https://doi.org/10.1002/advs.202505087

Vancouver

Jia R, Liu Y, Xiao J, Xia Y, Zhao X, Ma H, et al. A ROS‐Responsive Dual‐Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T‐Cell Acute Lymphoblastic Leukemia. Advanced Science. 2025;12(31). doi:10.1002/advs.202505087

BibTeX
@article{Jia2025,
  author = {Jia, Ruinan and Liu, Yang and Xiao, Jilong and Xia, Yuan and Zhao, Xin and Ma, Huixian and Ye, Jingjing and Zhang, Zhiyue and Sun, Tao and Ji, Chunyan},
  title = {A ROS‐Responsive Dual‐Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T‐Cell Acute Lymphoblastic Leukemia},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {31},
  doi = {10.1002/advs.202505087}
}
Kostenlos starten →